IL17A and psoriasis: This observation aligns with longitudinal evidence demonstrating that systemic anti-psoriasis therapies, particularly IL-17/IL-23 targeted biologics, exert beneficial effects not only on cutaneous manifestations but also improve metabolic parameters including HbA1c reduction and HDL-C elevation1.